Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 31, 2022
[ Wed, Aug 31st 2022
] - WOPRAI
[ Wed, Aug 31st 2022
] - WOPRAI
Tue, August 30, 2022
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
[ Tue, Aug 30th 2022
] - WOPRAI
Mon, August 29, 2022
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
[ Mon, Aug 29th 2022
] - WOPRAI
John Eade Upgraded (AZN) to Strong Buy and Held Target at $75 on, Aug 29th, 2022
John Eade of Argus Research, Upgraded "AstraZeneca PLC" (AZN) to Strong Buy and Held Target at $75 on, Aug 29th, 2022.
John has made no other calls on AZN in the last 4 months.
There is 1 other peer that has a rating on AZN. Out of the 1 peers that are also analyzing AZN, 0 agree with John's Rating of Hold.
This is the rating of the analyst that currently disagrees with John
- Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $75 on, Wednesday, May 4th, 2022
